Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
GSK’s Terrell On ‘Relentless’ Digital Consumption Across the Spectrum
Cipla Backs Start-Up As It Builds Digital Health Strategy
Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy
When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.
Glenmark Spins Out Innovation With New US Base
Sun’s Ilumya Gnaws At US Psoriasis Market
Around 800 physicians have prescribed Sun’s Ilumya, giving it some early traction in the competitive US psoriasis market. The Indian firm is striving to push harder and will also take a call on pursuing additional indications for the product.
Lupin's US Generics Turn Corner, Spotlight On Upcoming Launches
Cipla Bullish For Future, Caps Speculation On Top-Level Departures
After a tough Q3, Cipla indicates that things are looking up as it readies to enter fiscal 2020, with both the US and India businesses shaping up well. The company also sought to dispel concerns around top level exits.
What GSK's Immunology Chief Did Next
Paul Peter Tak recently defected from big pharma to East Coast venture firm Flagship Pioneering. He described the appeal of entrepreneurship in the biotech world and the value of taking the road less traveled when it comes to biomedical R&D.
Record Dr Reddy's US Launches In Q3 Set Tone For Earnings Pick Up?
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.